Phenprocoumon



Indications and Reactions:

Role Indications Reactions
Primary
Drug Use For Unknown Indication 17.6%
Atrial Fibrillation 11.8%
Aortic Valve Replacement 7.8%
Cardiac Failure Chronic 7.8%
Hypertension 7.8%
Thrombosis Prophylaxis 7.8%
Coronary Artery Disease 5.9%
Coronary Arterial Stent Insertion 3.9%
Essential Hypertension 3.9%
Hyperlipidaemia 3.9%
Prophylaxis Against Gastrointestinal Ulcer 3.9%
Age-related Macular Degeneration 2.0%
Atrial Flutter 2.0%
Dyslipidaemia 2.0%
Fungal Infection 2.0%
Heart Valve Replacement 2.0%
Intertrigo 2.0%
Myocardial Ischaemia 2.0%
Pain 2.0%
Pulmonary Embolism 2.0%
International Normalised Ratio Increased 28.6%
Gastrointestinal Haemorrhage 21.4%
Anaemia 7.1%
Cutaneous Lupus Erythematosus 7.1%
Liver Injury 7.1%
Oesophagitis Haemorrhagic 7.1%
Prothrombin Time Prolonged 7.1%
Subdural Haematoma 7.1%
Toxicity To Various Agents 7.1%
Secondary
Product Used For Unknown Indication 25.9%
Drug Abuse 23.6%
Hypertension 8.7%
Drug Use For Unknown Indication 8.6%
Atrial Fibrillation 6.6%
Coronary Artery Disease 4.2%
Thrombosis Prophylaxis 3.6%
Aortic Valve Replacement 3.5%
Chronic Obstructive Pulmonary Disease 2.3%
Hyperlipidaemia 2.3%
Atrial Flutter 1.3%
Epilepsy 1.3%
Dermatitis 1.2%
Prophylaxis 1.1%
Grand Mal Convulsion 1.0%
Pruritus 1.0%
Rheumatoid Arthritis 0.9%
Tachycardia Paroxysmal 0.9%
Type 2 Diabetes Mellitus 0.9%
Essential Hypertension 0.8%
Cutaneous Lupus Erythematosus 11.3%
Toxic Epidermal Necrolysis 11.3%
Drug Interaction 10.0%
Gastrointestinal Haemorrhage 10.0%
Prothrombin Time Prolonged 7.5%
Gastritis Haemorrhagic 5.0%
Hyperglycaemia 5.0%
Rib Fracture 5.0%
Vomiting 5.0%
Epistaxis 3.8%
International Normalised Ratio Increased 3.8%
Concomitant Disease Progression 2.5%
Fallot's Tetralogy 2.5%
General Physical Health Deterioration 2.5%
Haematuria 2.5%
Haemorrhage 2.5%
Hyperkalaemia 2.5%
Mucosal Haemorrhage 2.5%
Oesophagitis Haemorrhagic 2.5%
Pancreatitis Acute 2.5%
Concomitant
Product Used For Unknown Indication 19.7%
Drug Use For Unknown Indication 16.5%
Atrial Fibrillation 13.7%
Hypertension 11.5%
Renal Failure Chronic 5.8%
Rheumatoid Arthritis 4.9%
Pain 3.5%
Prophylaxis 2.7%
Cardiac Failure 2.6%
Coronary Artery Disease 2.5%
Prostate Cancer 2.2%
Hyperparathyroidism Secondary 2.0%
Hyperlipidaemia 1.8%
Diabetes Mellitus 1.8%
Osteoporosis 1.6%
Cardiac Failure Congestive 1.5%
Hypercholesterolaemia 1.5%
Anticoagulant Therapy 1.5%
Thrombosis Prophylaxis 1.5%
Type 2 Diabetes Mellitus 1.5%
Hepatic Enzyme Increased 9.1%
Renal Failure Acute 9.1%
Fatigue 7.0%
Pain 7.0%
Sepsis 6.4%
Wrong Technique In Drug Usage Process 5.9%
Dyspnoea 4.8%
Rhabdomyolysis 4.8%
Anal Fissure 4.3%
Pleural Effusion 4.3%
Pyrexia 4.3%
Allergic Granulomatous Angiitis 3.7%
Cardiac Failure 3.7%
Gastritis Erosive 3.7%
Haemorrhoids 3.7%
Multi-organ Failure 3.7%
Oedema Peripheral 3.7%
Palpitations 3.7%
Weight Decreased 3.7%
Hypersensitivity 3.2%
Interacting
Product Used For Unknown Indication 46.1%
Drug Use For Unknown Indication 12.2%
Atrial Fibrillation 6.1%
Pulmonary Arterial Hypertension 5.2%
Hypertension 2.6%
Ill-defined Disorder 2.6%
Intertrigo 2.6%
Prophylaxis 2.6%
Renal Transplant 2.6%
Acute Myocardial Infarction 1.7%
Breast Cancer 1.7%
Fungal Infection 1.7%
Fungal Skin Infection 1.7%
Hyperlipidaemia 1.7%
Rash 1.7%
Renal Failure Chronic 1.7%
Respiratory Tract Infection 1.7%
Thrombosis Prophylaxis 1.7%
Anaemia 0.9%
Bladder Disorder 0.9%
International Normalised Ratio Increased 33.3%
Drug Interaction 13.3%
Coagulation Test Abnormal 6.7%
Haemorrhage 6.7%
Prothrombin Time Abnormal 6.7%
Gastrointestinal Haemorrhage 3.3%
Haematemesis 3.3%
Haematuria 3.3%
Hyperkalaemia 3.3%
International Normalised Ratio Abnormal 3.3%
International Normalised Ratio Decreased 3.3%
Prothrombin Time Prolonged 3.3%
Respiratory Tract Haemorrhage 3.3%
Urogenital Haemorrhage 3.3%
Visual Acuity Reduced 3.3%